Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data Meeting Abstract
| Authors: | Cella, D.; Motzer, R. J.; May, J.; Wallace, J.; Marteau, F.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Ejzykowicz, F.; Choueiri, T. K. |
| Abstract Title: | Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604021 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.6567 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6567 -- Source: Wos |
